ArticleTranslational and clinical pharmacology2024
Advanced clinical symptoms of the antihangover compound HK-GCM-H01 in healthy Koreans.
Article in Translational and clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Theracurmin Products for Alleviating Alcohol Hangovers in Healthy Adults.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A hangover is a combination of negative mental and physical symptoms, such as headache, diarrhea, and loss of appetite, that occur after alcohol consumption and can vary depending on individual genetic and environmental factors. To quickly relieve these hangover symptoms, a new hangover relief compound called HK-GCM-H01 has been developed. This compound, HK-GCM-H01, consists of fermented rice germ extracts, yeast extract mixtures, cili extract powder, and concentrated nipafam powder, all of which are known to relieve hangover symptoms. The safety and clinical symptoms of HK-GCM-H01 were evaluated, along with the pharmacokinetic properties of alcohol and acetaldehyde after its administration. This study was conducted on 50 healthy Korean men using a randomized, double-blind, placebo-controlled, single-intake, crossover design. To evaluate clinical symptoms, Acute Hangover Scale and Alcohol Hangover Severity Scale were used, and the pharmacokinetic evaluation parameters included the maximum plasma concentration, the time to peak plasma concentration, the terminal half-life, and the area under the plasma concentration-time curve from X hours to Y hours. A significant reduction in clinical symptoms was observed after alcohol consumption in the group that consumed HK-GCM-H01 with added hangover relief compound, as was a significant decrease in blood exposure to acetaldehyde compared to the placebo group. There were no adverse events or significant changes in liver function indicators reported during the safety evaluation. These findings indicate that HK-GCM-H01 is safe and significantly reduces plasma concentrations of acetaldehyde, the main cause of hangover, suggesting that it improves hangover symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.